Open access
Sep 2026
Real-World Effectiveness of Nirsevimab Against RSV-LRTI and Bronchiolitis Hospitalization: Results from the 2024–2025 Italian Universal Immunization Campaign in Newborns
Respiratory syncytial virus (RSV) remains a leading cause of lower respiratory tract infection (LRTI) and hospitalization in early infancy. Following the introduction of universal nirsevimab prophylaxis in Italy during the 2024–2025 RSV season, we evaluated its real-world effectiveness against RSV-associated hospitaliz...
C. Auriti, Camilla Gizzi, Matteo Riccò et al.
· Viruses · 0 citations